A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
NCT ID: NCT07128199
Last Updated: 2025-12-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
360 participants
INTERVENTIONAL
2025-11-30
2032-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Approximately 360 participants will be randomized 1:1 to:
Arm A: Platinum-based chemotherapy (cisplatin or carboplatin plus pemetrexed) in combination with zipalertinib 100 milligrams (mg) twice daily (BID), followed by zipalertinib 100 mg BID alone OR
Arm B: Platinum-based chemotherapy (cisplatin or carboplatin plus pemetrexed) in combination with placebo BID, followed by placebo BID alone.
The duration of 1 treatment cycle will be 21 days. An independent data monitoring committee (IDMC) will be established to monitor interim safety data.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Zipalertinib
Participants will receive adjuvant platinum-based chemotherapy consisting of cisplatin 75 milligrams per square meter (mg/m\^2) or carboplatin (area under concentration \[AUC\] 5 milligrams per milliliter per minute mg/mL/min) plus pemetrexed 500 mg/m\^2, administered via intravenous (IV) infusion, on 21-day cycle, in combination with zipalertinib 100 mg, orally, twice daily (BID).
After completion of chemotherapy, participants will continue on zipalertinib monotherapy 100 mg, orally, BID on 21-day cycle, until the participant meets any of the treatment discontinuation criteria.
Cisplatin
IV infusion.
Carboplatin
IV infusion.
Pemetrexed
IV infusion.
TAS6417
Oral tablets.
Placebo
Participants will receive adjuvant platinum-based chemotherapy consisting of cisplatin 75 mg/m\^2 or carboplatin AUC 5 mg/mL/min plus pemetrexed 500 mg/m\^2, administered via IV infusion, on 21-day cycle, in combination with zipalertinib matching-placebo 100 mg, orally, BID.
After completion of chemotherapy, participants will continue on zipalertinib matching-placebo monotherapy 100mg, orally, BID on 21-day cycle, until the participant meets any of the treatment discontinuation criteria.
Cisplatin
IV infusion.
Carboplatin
IV infusion.
Pemetrexed
IV infusion.
Zipalertinib Matching-placebo
Oral tablets.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cisplatin
IV infusion.
Carboplatin
IV infusion.
Pemetrexed
IV infusion.
TAS6417
Oral tablets.
Zipalertinib Matching-placebo
Oral tablets.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Documented EGFRmt status as determined by local testing performed at a clinical laboratory improvement amendment (CLIA) certified (United States \[US\]) or accredited (outside of the US) local laboratory, defined as either one of the following EGFRmt:
1. exon20 insertion mutations (ex20ins) or
2. other uncommon, non-ex20ins EGFRmt (eg, G719X, L861Q, or S768I)
3. Magnetic resonance imaging (MRI) or computed tomography (CT) scan of the brain done prior to surgery. Participants in whom this was not done prior to surgery may still be enrolled if appropriate imaging (i.e., MRI or CT of the brain) is performed prior to randomization.
4. Complete surgical resection of the primary NSCLC is mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for tumor. Resection may be accomplished by open thoracotomy or video associated thoracic surgery (VATS) techniques.
5. Classified post-operatively as either Stage IB, IIA, IIB, or IIIA according to the tumor nodes metastasis (TNM) staging system for lung cancer (American Joint Committee on Cancer \[AJCC\] 9th edition).
6. Complete recovery from surgery at the time of randomization.
7. Eastern cooperative oncology group performance status (ECOG PS) of 0 or 1.
8. Archival tumor tissue available for submission, with minimum quantity sufficient to evaluate EGFRmt status and, where possible, other biomarkers.
Exclusion Criteria
2. Treatment with any of the following within the time frame specified:
1. Zipalertinib (TAS6417/CLN-081) or any other EGFR inhibitor at any time.
2. Pre-operative or post-operative or planned radiation therapy for the current lung cancer.
3. Any prior systemic anticancer therapy (e.g., neoadjuvant chemotherapy), including investigational therapy, for treatment of NSCLC.
4. Major surgery (including primary tumor surgery, excluding placement of vascular access) within 4 weeks of the first dose of study treatment.
5. All prescribed medication, over-the-counter medication, vitamin preparations and other food supplements, or herbal medications that are strong or moderate cytochrome p450 (CYP) 3A4 inducers or inhibitors within 7 days prior to first dose.
6. Treatment with an investigational drug within five half-lives of the compound or any of its related material, if known.
3. Has received only segmentectomies or wedge resections.
4. Past medical history of interstitial lung disease (ILD)/pneumonitis, drug-induced ILD/pneumonitis or any evidence of clinically active ILD/pneumonitis.
5. Impaired cardiac function or clinically significant cardiac disease.
6. Unable to swallow tablets or has any disease or condition that may significantly affect gastrointestinal (GI) absorption of zipalertinib (such as inflammatory bowel disease, malabsorption syndrome, or prior significant bowel resection).
7. Participants with a history of any other cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer, other cancers curatively treated with no evidence of disease for \>5 years following the end of treatment and which, in the opinion of the treating physician, do not have a substantial risk of recurrence of the prior malignancy.
8. Known history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) that is unstable or not controlled with treatment. Screening not required.
9. Active bleeding disorders.
10. Known:
a. Hypersensitivity: i. To the ingredients in zipalertinib/placebo or any drugs similar in structure or class. ii. To platinum-containing drugs (i.e., cisplatin, carboplatin), pemetrexed, or any known excipients of these drugs. b. Contraindications to platinum-containing drugs (i.e., cisplatin, carboplatin) or pemetrexed according to the respective local labels.
11. Is unable or unwilling to take dexamethasone, folic acid, and/or vitamin B12 supplementation during treatment with pemetrexed.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Taiho Oncology, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alaska Oncology and Hematology
Anchorage, Alaska, United States
City of Hope Comprehensive Cancer Center - Duarte
Duarte, California, United States
Georgetown University School of Medicine
Washington D.C., District of Columbia, United States
D&H Cancer Research Center - Margate
Margate, Florida, United States
Alpha Oncology Research
Orange City, Florida, United States
University of Illinois Medical Center
Chicago, Illinois, United States
Profound Research LLC at Michigan Hematology and Oncology Consultants
Dearborn, Michigan, United States
Henry Ford Health System
Detroit, Michigan, United States
Perlmutter Cancer Center - 34th Street
New York, New York, United States
Memorial Sloan Kettering Cancer Center - New York
New York, New York, United States
Atrium Health Wake Forest Baptist - Comprehensive Cancer Center
Charlotte, North Carolina, United States
Gabrail Cancer and Research Center
Canton, Ohio, United States
Virginia Cancer Specialists - Fairfax Office
Fairfax, Virginia, United States
Instituto Argentino de Diagnóstico y Tratamiento
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Centro de Investigación Pergamino SA
Pergamino, Buenos Aires, Argentina
Hospital Universitario Austral
Pilar, Buenos Aires, Argentina
CEMAIC - Centro de Especialidades Médicas Ambulatorias e Investigación Clínica
Córdoba, , Argentina
Bankstown-Lidcombe Hospital
Bankstown, New South Wales, Australia
GenesisCare - North Shore
St Leonards, New South Wales, Australia
Saint John of God - Subiaco Hospital
Subiaco, Western Australia, Australia
Universitair Ziekenhuis Antwerpen
Edegem, Antwerpen, Belgium
Universitair Ziekenhuis (UZ) Leuven - Campus Gasthuisberg
Leuven, Flemish Brabant, Belgium
NOHC - Núcleo de Oncologia e Hematologia do Ceará - José Lourenço
Fortaleza, Ceará, Brazil
Centro Regional Integrado de Oncologia
Fortaleza, Ceará, Brazil
Centro de Pesquisas Clínicas Em Oncologia - CPCO
Cachoeiro de Itapemirim, Espírito Santo, Brazil
Hospital Santa Rita
Vitória, Espírito Santo, Brazil
Núcleo de Oncologia da Bahia Ondina - NOB
Salvador, Estado de Bahia, Brazil
Oncoclinicas Oncovida - Brasilia
Brasília, Federal District, Brazil
Cetus Oncologia - Unidade Belo Horizonte
Belo Horizonte, Minas Gerais, Brazil
Cenantron Centro Avançado de Tratamento Oncológico
Belo Horizonte, Minas Gerais, Brazil
Centro Integrado de Oncologia de Curitiba (CIONC)
Curitiba, Paraná, Brazil
Instituto de Medicina Integral Professor Fernando Figueira
Recife, Pernambuco, Brazil
Centro de Pesquisa Vencer e Oncoclínica - Teresina
Teresina, Piauí, Brazil
Instituto D'Or de Pesquisa e Ensino - Rio de Janeiro
Botafogo, Rio de Janeiro, Brazil
Liga Contra o Câncer - Centro Avançado de Oncologia
Natal, Rio Grande do Norte, Brazil
Clínica Viver
Centro Santa Maria, Rio Grande do Sul, Brazil
Hospital Bruno Born
Lajeado, Rio Grande do Sul, Brazil
Hospital São Vicente de Paulo
Passo Fundo, Rio Grande do Sul, Brazil
Irmandade da Santa Casa de Misericórdia Hospital - Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Irmandade da Santa Casa de Misericórdia Hospital - Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Mãe de Deus - Centro Integrado de Oncologia
Porto Alegre, Rio Grande do Sul, Brazil
Grupo ELORA
Florianópolis, Santa Catarina, Brazil
CHO Centro - Centro de Hematologia e Oncologia de Joinville
Joinville, Santa Catarina, Brazil
Fundação Pio XII - Hospital de Câncer de Barretos - Hospital de Amor
Barretos, São Paulo, Brazil
Hospital Amaral Carvalho
Jaú, São Paulo, Brazil
Instituto de Oncologia de Sorocaba
Sorocaba, São Paulo, Brazil
A Beneficência Portuguesa de São Paulo
São Paulo, , Brazil
Instituto de Assistência Médica ao Servidor Público Estadual
São Paulo, , Brazil
London Health Sciences Centre
London, Ontario, Canada
William Osler Health System - Brampton Civic Hospital
Montreal, Quebec, Canada
Hôpital Saint-André
Bordeaux, Aquitane, France
Centre Léon Bérard
Lyon, Auvergne-Rhône-Alpes, France
Centre Hospitalier Lyon-Sud
Pierre-Bénite, Auvergne-Rhône-Alpes, France
L'Hôpital Nord-Ouest (HNO) - Villefranche-sur-Saône
Villefranche-de-Rouergue, Aveyron, France
Hôpital Côte De Nacre
Caen, Basse-Normandie, France
Centre Hospitalier Universitaire de Nîmes
Nîmes, Gard, France
Hôpital Emile Muller
Mulhouse, Grand Est, France
Hôpital Pontchaillou
Rennes, Ille-et-Vilaine, France
Centre Hospitalier Universitaire De Nantes - Hôpital Nord Laennec
Saint-Herblain, Loire-Atlantique, France
Centre Hospitalier Universitaire d'Angers
Angers, Maine-et-Loire, France
CHU d Angers
Angers, Maine-et-Loire, France
Institut de Cancérologie de l'Ouest - Angers
Angers, Maine-et-Loire, France
CHU de Nimes - Caremeau Nord
Nîmes, Occitanie, France
Centre Hospitalier Le Mans
Le Mans, Pays de la Loire Region, France
Hopital Prive du Confluet
Nantes, Pays de la Loire Region, France
Hôpital Privé du Confluent
Nantes, Pays de la Loire Region, France
Hopital Nord Ouest
Gleizé, Rhône, France
Gustave Roussy
Villejuif, , France
Hôpital Ambroise-Paré
Boulogne-Billancourt, Île-de-France Region, France
Centre Hospitalier Intercommunal de Créteil
Créteil, Île-de-France Region, France
Groupe Hospitalier Paris Saint-Joseph
Paris, Île-de-France Region, France
Hôpital Bichat - Claude-Bernard
Paris, Île-de-France Region, France
SLK-Kliniken - Fachklinik Löwenstein
Löwenstein, Baden-Wurttemberg, Germany
Krankenhaus Nordwest
Frankfurt am Main, Hesse, Germany
Universitätsklinikum Gießen und Marburg - Gießen
Giessen, Hesse, Germany
Kliniken der Stadt Köln
Cologne, North Rhine-Westphalia, Germany
Saint Savvas Anticancer - Oncological Hospital of Athens
Athens, Attica, Greece
General Hospital for Thoracic Diseases Sotiria
Athens, Attica, Greece
Metaxa Cancer Hospital of Piraeus
Athens, Attica, Greece
BioClinic Thessaloniki
Athens, Central Macedonia, Greece
Interbalkan Medical Center of Thessaloniki
Thessaloniki, Central Macedonia, Greece
Humanity & Health Clinical Trial Centre
Hong Kong, , Hong Kong
Queen Mary Hospital - Hong Kong
Hong Kong, , Hong Kong
Princess Margaret Hospital
Kowloon, , Hong Kong
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST
Meldola, Forlì-Cesena, Italy
Azienda Socio Sanitaria Territoriale (ASST) di Bergamo Ovest
Legnano, Milan, Italy
Fondazione IRCCS - Istituto Nazionale dei Tumori
Milan, Milan, Italy
Istituto Europeo di Oncologia
Milan, Milan, Italy
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
Milan, Milan, Italy
Ospedale del Mare
Napoli, Naples, Italy
Ospedale Santa Maria delle Croci di Ravenna
Lugo, Ravenna, Italy
Azienda Ospedaliera Complesso Ospedaliero San Giovanni - Addolorata
Roma, Rome, Italy
Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia
Candiolo, Torino, Italy
Azienda Ospedaliero - Universitaria San Luigi Gonzaga
Orbassano, Torino, Italy
Ospedale P. Pederzoli - Casa di Cura Privata S.p.A.
Peschiera del Garda, Verona, Italy
Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo - Alessandria
Alessandria, , Italy
Azienda Ospedaliero Universitaria Delle Marche
Ancona, , Italy
Humanitas Gavazzeni
Bergamo, , Italy
Azienda Socio Sanitaria Territoriale (ASST) Papa Giovanni XXIII
Bergamo, , Italy
Azienda Ospedaliero-Universitaria di Bologna - Policlinico Sant Orsola-Malpighi
Bologna, , Italy
Azienda Ospedaliero Universitaria Policlinico Gaspare Rodolico - San Marco - Catania/ Presidio G. Rodolico
Catania, , Italy
Azienda Unita Sanitaria Locale toscana Nord Ovest
Livorno, , Italy
Azienda Unità Sanitaria Locale Toscana Nord Ovest
Livorno, , Italy
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele
Milan, , Italy
Azienda Ospedaliero - Universitaria di Modena
Modena, , Italy
Fondazione IRCCS Policlinico San Matteo
Pavia, , Italy
Azienda Ospedaliera Universitaria Senese - L'ospedale Santa Maria alle Scotte
Siena, , Italy
Azienda Ospedaliera Universitaria Integrata Verona
Verona, , Italy
Aichi Cancer Center
Nagoya, Aiti [Aichi], Japan
Kurume University Hospital
Kurume-Shi, Fukuoka, Japan
Hiroshima University Hospital
Hiroshima, Hirosima [Hiroshima], Japan
National Hospital Organization Kyushu Cancer Center
Fukuoka, Hukuoka [Fukuoka], Japan
Hyogo Cancer Center
Akashi, Hyōgo, Japan
Kobe University Hospital
Kobe, Hyōgo, Japan
Kanagawa Cancer Center
Yokohama, Kanagawa, Japan
Tohoku University Hospital
Sendai, Miyagi, Japan
Nagasaki University Hospital
Nagasaki, Nagasaki, Japan
Kansai Medical University Hospital
Hirakata, Osaka, Japan
Kindai University Hospital
Osakasayama-Shi, Osaka, Japan
Shizuoka Cancer Center
Sunto-gun, Sizuoka [Shizuoka], Japan
National Cancer Center Hospital East
Kashiwa-shi, Tiba [Chiba], Japan
Cancer Institute Hospital of JFCR
Koto, Tokyo, Japan
Okayama University Hospital
Okayama, , Japan
Osaka City General Hospital
Osaka, , Japan
Osaka Prefectural Hospital Organization - Osaka International Cancer Institute
Osaka, , Japan
Hospital Raja Perempuan Zainab II
Kota Bharu, Kelantan, Malaysia
Hospital Pulau Pinang
Pulau Pinang, Pulau Pinang, Malaysia
Hospital Picaso
Petaling Jaya, Selangor, Malaysia
Hospital Kuala Lumpur
Kuala Lumpur, , Malaysia
Sunway Medical Centre
Selangor Darul Ehsan, , Malaysia
Preparaciones Oncológicas S.C.
León, Guanajuato, Mexico
Centro Oncológico Alianza XXI
Mexico City, Mexico City, Mexico
Clínica Integral Internacional de Oncología S de RL de CV
Mirador, Puebla, Mexico
Ziekenhuis St Jansdal Harderwijk
Harderwijk, Gelderland, Netherlands
Radboud Universitair Medisch Centrum
Nijmegen, Gelderland, Netherlands
Leids Universitair Medisch Centrum (LUMC)
Leiden, South Holland, Netherlands
Hospital Nacional Arzobispo Loayza
Lima Cercado, Lima region, Peru
IPOR - Instituto Peruano de Oncología & Radioterapia - Sede Principal
San Isidro, Lima region, Peru
Detecta Clínica
Surquillo, Lima region, Peru
Przychodnia Lekarska KOMED Roman Karaszewski
Konin, Greater Poland Voivodeship, Poland
4 Wojskowy Szpital Kliniczny z Polikliniką SP ZOZ
Wroclaw, Lower Silesian Voivodeship, Poland
Mruk-Med I Sp. z o.o.
Rzeszów, Podkarpackie Voivodeship, Poland
Warmińsko-mazurskie Centrum Chorób Płuc w Olsztynie
Olsztyn, Warmian-Masurian Voivodeship, Poland
Wojewódzki Szpital Specjalistyczny w Białej Podlaskiej
Biała Podlaska, , Poland
Institutul Oncologic Bucuresti - Prof. Dr. Alexandru Trestioreanu
Bucharest, Bucharest, Romania
Monza Oncology Day Hospital
Bucharest, București, Romania
Centrul de Radioterapie Amethyst Cluj
Floreşti, Cluj, Romania
Ovidius Clinical Hospital
Ovidiu, Constanța County, Romania
Clinica MC Gral Ploiesti
Ploieşti, Prahova, Romania
Oncocenter - Oncologie Clinica
Timișoara, Timiș County, Romania
Spitalul Județean de Urgență Satu Mare
Satu Mare, , Romania
Tan Tock Seng Hospital
Singapore, North East, Singapore
National Cancer Centre Singapore
Singapore, , Singapore
Kyungpook National University Chilgok Hospital
Daegu, Daegu Gwang'yeogsi [Taegu-Kwangyokshi], South Korea
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Catholic University of Korea St. Vincent's Hospital
Suwon, Gyeonggi-do, South Korea
Ajou University Hospital
Suwon, Gyeonggi-do, South Korea
Chungbuk National University Hospital
Cheongju-si, Gyeonggido [Kyonggi-do], South Korea
National Cancer Center - Korea
Goyang-si, Gyeonggido [Kyonggi-do], South Korea
Keimyung University Dongsan Hospital
Daegu, Gyeongsangbugdo [Kyongsangbuk-do], South Korea
Kosin University Gospel Hospital
Pusan, Gyeongsangnam-do, South Korea
Pusan National University Yangsan Hospital
Yangsan, Gyeongsangnam-do, South Korea
Gyeongsang National University Hospital
Jinju, Gyeongsangnamdo [Kyongsangnam-do], South Korea
Inha University Hospital
Incheon, Incheon Gwang'yeogsi [Inch'on-Kwangyokshi], South Korea
Chonnam National University Hwasun Hospital
Hwasun-gun, Jeollanam-do, South Korea
Jeonbuk National University Hospital
Jeonju, Jeonrabugdo [Chollabuk-do], South Korea
Korea University Anam Hospital
Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], South Korea
Severance Hospital
Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], South Korea
Konkuk University Medical Center
Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], South Korea
The Catholic University of Korea - Seoul St. Mary's Hospital
Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], South Korea
Korea University Guro Hospital
Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], South Korea
Hanyang University Hospital
Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], South Korea
Seoul National University Hospital
Seoul, Seoul Teugbyeolsi, South Korea
Seoul Metropolitan Government Seoul National University Boramae Medical Center
Seoul, , South Korea
Hospital Universitario Son Espases
Palma de Mallorca, Balearic Islands, Spain
Institut Català d'Oncologia Badalona
Badalona, Barcelona, Spain
Complejo Hospitalario Universitario Insular Materno Infantil
Las Palmas de Gran Canaria, Las Palmas, Spain
Hospital Universitario Puerta de Hierro - Majadahonda
Majadahonda, Madrid, Spain
Hospital Universitari Sant Joan de Reus
Reus, Tarragona, Spain
Instituto Oncológico Dr Rosell
Barcelona, , Spain
Hospital Universitari Vall d'Hebrón
Barcelona, , Spain
Hospital Universitario Clínico San Cecilio PTS
Granada, , Spain
Hospital Universitario Lucus Augusti
Lugo, , Spain
MD Anderson Cancer Center Madrid
Madrid, , Spain
Hospital Universitario Fundación Jiménez Díaz
Madrid, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Hospital Quirónsalud Málaga
Málaga, , Spain
Hospital Universitario Virgen del Rocío
Seville, , Spain
Hospital Universitari i Politècnic La Fe
Valencia, , Spain
Chulabhorn Hospital
Bang Kapi, Bangkok, Thailand
Faculty of Medicine Siriraj Hospital
Bangkoknoi, Bangkok, Thailand
Lampang Cancer Hospital
Muang, Changwat Lampang, Thailand
Songklanagarind Hospital
Hat Yai, Changwat Songkhla, Thailand
Navamindradhiraj University - Faculty of Medicine Vajira Hospital
Bangkok, Khet Dusit, Thailand
Başkent Üniversitesi Adana Dr Turgut Noyan Uygulama ve Araştirma Merkezi
Yüreğir, Adana, Turkey (Türkiye)
Ankara Il Saglik Mudurlugu SBU Gulhane Egitim Ve Arastirma Hastanesi
Etlik, Ankara, Turkey (Türkiye)
Dicle Üniversitesi Tıp Fakültesi
Sur, Diyarbakır, Turkey (Türkiye)
Gaziantep Universitesi - Şahinbey Araştırma ve Uygulama Hastanesi
Şehitkamil, Gaziantep, Turkey (Türkiye)
Memorial Bahçelievler Hospital
Bahçelievler, Istanbul, Turkey (Türkiye)
İstinye Üniversite Hastanesi Liv Hospital Bahcesehir
Esenyurt, Istanbul, Turkey (Türkiye)
İ.A.Ü. VM Medical Park Florya Hastanesi
Küçükçekmece, Istanbul, Turkey (Türkiye)
Medicana International Izmir Hastanesi
Turgutlu, Manisa, Turkey (Türkiye)
VM Medical Park Samsun Hastanesi
Atakum, Samsun, Turkey (Türkiye)
Medical Park Seyhan Hastanesi
Adana, , Turkey (Türkiye)
T.C. Saglik Bakanligi Adana Sehir Egitim ve Arastirma Hastanesi
Adana, , Turkey (Türkiye)
Memorial Ankara Hastanesi
Ankara, , Turkey (Türkiye)
Liv Hospital Ankara
Ankara, , Turkey (Türkiye)
Trakya Üniversitesi Sağlık Araştırma ve Uygulama Merkezi
Edirne, , Turkey (Türkiye)
Ozel Gaziantep Medical Point Hastanesi
Gaziantep, , Turkey (Türkiye)
T.C. Saglik Bakanligi - Istanbul Il Saglik Mudurlugu - Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi
Istanbul, , Turkey (Türkiye)
Izmir Ekonomi Universitesi Medical Point Hastanesi
Izmir, , Turkey (Türkiye)
The Christie NHS Foundation Trust
Manchester, England, United Kingdom
Nottingham University Hospitals NHS Trust
Nottingham, England, United Kingdom
Velindre University NHS Trust
Cardiff, Wales, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-521775-31-00
Identifier Type: OTHER
Identifier Source: secondary_id
TAS6417-302
Identifier Type: -
Identifier Source: org_study_id